Femasys (FEMY) EBT Margin (2020 - 2026)
Femasys' (FEMY) quarterly EBT Margin came in at 1346.55% in Q2 2026, down 22604.0% on a YoY basis from N/an in Q2 2025, and down 20.17% quarter-over-quarter from 1120.52% in Q2 2025.
Powered by 
Analysis
Femasys (FEMY) EBT Margin (2020 - 2026) Analysis & Trends
Femasys (FEMY) has reported EBT Margin for 7 consecutive years, with 1346.55% the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, EBT Margin fell 22604.0% year-over-year to 1346.55%; the trailing twelve-month figure through Jun 2026 stood at 1206.1% (down 9280.0% YoY), and the FY2025 full-year result was 812.21%, up 34222.0% from the prior year.
- EBT Margin eased to 1346.55% in Q2 2026 per FEMY's latest filing, from 1120.52% in the prior quarter.
- Across five years, EBT Margin topped out at 858.47% in Q3 2022 and bottomed at 2115.87% in Q2 2024.
- Historically, EBT Margin has averaged 1263.86% across 5 years, with a median of 1120.52% in 2025.
- The widest YoY moves for EBT Margin: up 118827 bps in 2024, down 121310 bps in 2024.
- Over 5 years, EBT Margin stood at 1231.88% in 2022, then slumped by 68 bps to 2067.52% in 2023, then soared by 57 bps to 879.25% in 2024, then slipped by 27 bps to 1120.52% in 2025, then slipped by 20 bps to 1346.55% in 2026.
- According to Business Quant data, EBT Margin over the past three periods registered 1346.55%, 1120.52%, and 1729.17% for Q2 2026, Q2 2025, and Q1 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 183.04 Bn | 177.44 Bn | 7.27 Bn | 12.10% |
| 2 | Intuitive Surgical | 125.02 Bn | 119.81 Bn | 1.96 Bn | 36.46% |
| 3 | Medtronic | 117.84 Bn | 109.02 Bn | 6.34 Bn | 18.13% |
| 4 | Stryker | 105.50 Bn | 102.02 Bn | 4.50 Bn | 23.74% |
| 5 | Boston Scientific | 66.27 Bn | 65.73 Bn | 3.85 Bn | 19.48% |
| 6 | Edwards Lifesciences | 49.60 Bn | 45.35 Bn | 1.35 Bn | 29.86% |
| 7 | Alcon | 33.70 Bn | 32.24 Bn | 1.68 Bn | -1.65% |
| 8 | Dexcom | 32.06 Bn | 30.11 Bn | 830.00 Mn | 24.27% |
| 9 | Steris | 21.02 Bn | 20.54 Bn | 684.20 Mn | 18.32% |
| 10 | Femasys | 9.37 Mn | 7.92 Mn | 189,391.00 | -1,346.55% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -1,346.55% |
| Jun 30, 2025 | -1,120.52% |
| Mar 31, 2025 | -1,729.17% |
| Dec 31, 2024 | -879.25% |
| Sep 30, 2024 | -974.52% |
| Jun 30, 2024 | -2,115.87% |
| Mar 31, 2024 | -1,327.55% |
| Dec 31, 2023 | -2,067.52% |
| Sep 30, 2023 | -1,635.66% |
| Jun 30, 2023 | -902.77% |
| Mar 31, 2023 | -1,002.18% |
| Dec 31, 2022 | -1,231.88% |
| Sep 30, 2022 | -858.47% |
| Jun 30, 2022 | -869.02% |
| Mar 31, 2022 | -897.01% |
| Dec 31, 2021 | -928.27% |
| Sep 30, 2021 | -838.23% |
| Jun 30, 2021 | -332.22% |
| Mar 31, 2021 | -554.99% |
| Dec 31, 2020 | -590.01% |